Enimmune Corp

ROCO:6564 (Taiwan)  
NT$ 28.30 (-2.08%) Nov 28
At Loss
P/B:
4.61
Market Cap:
NT$ 2.04B ($ 62.60M)
Enterprise V:
NT$ 1.58B ($ 48.48M)
Volume:
40.45K
Avg Vol (2M):
44.45K
Warning! GuruFocus detected 5 Severe warning signs with 6564. Try a 7-Day Free Trial to check it out.
Trade In:
Volume:
40.45K
Market Cap NT$:
2.04B
Market Cap $:
62.60M
At Loss
Avg Vol (2M):
44.45K
Enterprise Value NT$:
1.58B
Enterprise Value $:
48.48M
PB Ratio:
4.61
Alerts Website Sources Stock PDF
Dataset
Financial Download GuruFocus Premium Icon Manual of Stocksâ„¢

Business Description

Enimmune Corp

ISIN : TW0006564008
http://www.enimmune.com.tw
Dunhua South Road, 18th Floor-2, No. 76, Section 2, Da’an District, Taipei, TWN, 10683
Compare
Compare
ROCO:4724ROCO:6580ROCO:7427TPE:1733ROCO:6879ROCO:4194ROCO:4130ROCO:6846TPE:3164ROCO:6892OCSE:NOVO BVRTXREGNASX:CSLSGENXKRX:207940MRNAHKSE:02269XBRU:ARGXBNTX
Traded in other countries / regions
6564.Taiwan
IPO Date
2018-09-18
Description
Enimmune Corp is primarily engaged in the research and development and trading of vaccines, testing reagents and biotechnology services, etc., as well as trading of related western medicines.

Financial Strength

5/10
Name Current Vs Industry Vs History
Cash-To-Debt 5.43
Equity-to-Asset 0.56
Debt-to-Equity 0.23
Debt-to-EBITDA -0.44
Piotroski F-Score 3/9
0
1
2
3
4
5
6
7
8
9
Altman Z-Score 6.02
Distress
Grey
Safe
Beneish M-Score 2.07
Manipulator
Not Manipulator
WACC vs ROIC
WACC
ROIC

Growth Rank

5/10
Name Current Vs Industry Vs History
3-Year Revenue Growth Rate 15.6
3-Year EBITDA Growth Rate -40.4
3-Year EPS without NRI Growth Rate -34.5
3-Year FCF Growth Rate -0.1
3-Year Book Growth Rate -21.9

Momentum Rank

1/10
Name Current Vs Industry Vs History
5-Day RSI 27.07
9-Day RSI 27.2
14-Day RSI 27.82
6-1 Month Momentum % -9.62
12-1 Month Momentum % -18.77

Liquidity Ratio

Name Current Vs Industry Vs History
Current Ratio 2.7
Quick Ratio 2.66
Cash Ratio 2.34
Days Inventory 147.31
Days Sales Outstanding 83.99
Days Payable 61.09

Dividend & Buy Back

Name Current Vs Industry Vs History
3-Year Average Share Buyback Ratio -3.1
Shareholder Yield % -10.95

Profitability Rank

3/10
Name Current Vs Industry Vs History
Gross Margin % -29.51
Operating Margin % -450.58
Net Margin % -455.2
FCF Margin % -293.01
ROE % -56.33
ROA % -32.88
ROIC % -108.15
ROC (Joel Greenblatt) % -1392.24
ROCE % -46.08

GF Value Rank

3/10
Name Current Vs Industry Vs History
PS Ratio 36.99
PB Ratio 4.61
Price-to-Tangible-Book 6.07
EV-to-EBIT -6.55
EV-to-EBITDA -6.76
EV-to-Revenue 31.07
EV-to-FCF -11.38
Price-to-Net-Current-Asset-Value 6.72
Price-to-Net-Cash 9.5
Earnings Yield (Greenblatt) % -15.29
FCF Yield % -7.29

Financials

ROCO:6564's 30-Y Financials
AAPL
Income Statement Breakdown FY
No Enough Data
AAPL
Balance Sheet Breakdown
No Enough Data
AAPL
Cashflow Statement Breakdown
No Enough Data

Historical Operating Revenue by Business Segment

Historical Operating Revenue by Geographic Region

5-Step DuPont Analysis as of
No Enough Data

Guru Trades

See Details
To

Insider Trades

See Details
To

Peter Lynch Chart

Y-axis scale:
Interactive Chart
To

Performance

Dividend
Log
Bar
To

Annualized Return %  

Symbol
1 Week
1 Month
3 Months
6 Months
YTD
1 Year
3 Years
5 Years
10 Years

Total Annual Return %  

Symbol
2024
2023
2022
2021
2020
2019
2018
2017
2016
2015

Enimmune Corp Executives

Details

GF Value: NT$18.07

ROCO:6564

Valuation Chart

Year:

Analyst Estimate

Key Statistics

Name Value
Revenue (TTM) (Mil NT$) 50.82
EPS (TTM) (NT$) -3.484
Beta 0.24
Volatility % 17.82
14-Day RSI 27.82
14-Day ATR (NT$) 0.778271
20-Day SMA (NT$) 29.76
12-1 Month Momentum % -18.77
52-Week Range (NT$) 28.15 - 49.3
Shares Outstanding (Mil) 72.05

Piotroski F-Score Details

Year:
Component Result
Piotroski F-Score 3
Positive ROA
Positive CFROA
Higher ROA yoy
CFROA > ROA
Lower Leverage yoy
Higher Current Ratio yoy
Less Shares Outstanding yoy
Higher Gross Margin yoy
Higher Asset Turnover yoy

Enimmune Corp Filings

Filing Date Document Date Form
No Filing Data

Enimmune Corp Stock Events

Financials Calendars
Event Date Price(NT$)
No Event Data

Enimmune Corp Frequently Asked Questions

What is Enimmune Corp(ROCO:6564)'s stock price today?
The current price of ROCO:6564 is NT$28.30. The 52 week high of ROCO:6564 is NT$49.30 and 52 week low is NT$28.15.
When is next earnings date of Enimmune Corp(ROCO:6564)?
The next earnings date of Enimmune Corp(ROCO:6564) is .
Does Enimmune Corp(ROCO:6564) pay dividends? If so, how much?
Enimmune Corp(ROCO:6564) does not pay dividend.

Press Release

Subject Date
No Press Release
Research Tools
All-In-One Screener Stock Ideas Stock List Guru List Guru Real-Time Picks Insider List Insider Trades Economic Indicators Sector & Industry Performance DCF Calculator Discussion Board
Product
Pricing Plans Excel Add-In Google Sheets Add-on Data API Stock Comparison Table Manual of Stocks Mobile App 中文
Education
Financial Glossary Tutorials FAQ Schedule Free Session Buffett Indicator Shiller P/E Yield Curve Today U.S. Inflation Rate Global Market Valuation Fed Net Liquidity Buffett Assets Allocation
Company
About GuruFocus Career Contact Us Advertise Site Map Term of Use Privacy Policy Referral Program Partner Program
Survey

We'd love to learn more about your experiences on GuruFocus.com and how we can improve!

Take Survey
Follow Us
download GuruFocus on Apple store download GuruFocus on Google Play
Disclaimers
GuruFocus.com is not operated by a broker or a dealer. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes are provided by QuoteMedia, Inc. (CSI). Company fundamental data is provided by Morningstar. Analyst estimates data is sourced from both Refinitiv and Morningstar, with priority given to Refinitiv data. Data is updated daily.
© 2004-2024 GuruFocus.com, LLC. All Rights Reserved.